A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma

Second-line taxane-based therapy after first-line epothilone-B analog ixabepilone (BMS-247550) therapy




Epothilones and taxanes interfere with microtubule function. Ixabepilone, which is an epothilone-B analog, has activity against taxane-resistant cell lines and as first-line therapy for men with hormone-refractory prostate carcinoma (HRPC). Clinical cross-resistance of ixabepilone and taxanes in HRPC is unknown.


Records were evaluated retrospectively from patients with HRPC who were treated on a randomized Phase II trial of ixabepilone with or without estramustine and who subsequently received taxane chemotherapy. Posttherapy declines in prostate-specific antigen (PSA) levels and time to PSA progression were defined by consensus criteria. The median survival was evaluated by using the Kaplan–Meier method.


Forty-nine patients who received ixabepilone with estramustine (28 patients) or without estramustine (21 patients) subsequently received second-line taxane therapy. Second-line PSA declines ≥ 50% were achieved by 51% of patients (95% confidence interval [95% CI], 33–66%). Second-line PSA declines ≥ 50% were achieved by 61% of patients (95% CI, 42–78%) who achieved a first-line PSA decline ≥ 50% with ixabepilone, compared with 33% of patients (95% CI, 13–59%) who did not (P = 0.08). Patients who discontinued first-line ixabepilone treatment for disease progression were less likely to achieve a PSA decline ≥ 50% in response to second-line, taxane-based therapy compared with patients who discontinued for toxicity or patient preference (36% vs. 71%; P = 0.01).


Second-line taxane chemotherapy after ixabepilone resulted in a substantial frequency of PSA declines. Although patients with ixabepilone-refractory disease were less likely to respond to second-line taxane chemotherapy, 36% did achieve a PSA response. These findings were consistent with incomplete clinical cross-resistance between the taxanes and the epothilones. Cancer 2006. © 2005 American Cancer Society.